GlassScriptPhysician profile
Vasiliki Papathanasiou
NPI 1003046889
$5,339.50
in general payments reported to CMS, 2019-2025
44 companies · $904 in 2025
The $904 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.91 · 2020: $534 · 2021: $774 · 2022: $592 · 2023: $1,321 · 2024: $1,154 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,347 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,347.17 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $928.44 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $556.33 | 2020-2025 | |
| Glaxosmithkline, LLC. | $502.56 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $493.44 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $336.51 | 2020-2025 | |
| Amarin Pharma, INC. | $244.74 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $238.69 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.84 | 2020-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $187.62 | 2019-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $130.74 | 2021-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $121.76 | 2021-2024 | Injectafer |
| Lilly USA, LLC | $104.41 | 2021-2025 | Jardiance, Zepbound |
| Xeris Pharmaceuticals, INC. | $103.53 | 2020-2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $101.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $100.08 | 2020-2024 | Capvaxive, Belsomra, Gardasil 9 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vasiliki Papathanasiou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.